Copernicus Therapeutics, Inc. Receives Milestone Payment from Cystic Fibrosis Foundation Therapeutics, Inc. to Further Development of its Non-Viral Gene Therapy for Cystic Fibrosis

CLEVELAND--(BUSINESS WIRE)--Copernicus Therapeutics, Inc. announced today that it received a milestone payment from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), a non-profit affiliate of the Cystic Fibrosis Foundation. This milestone payment is part of a research, development, and commercialization agreement between CFFT and Copernicus to develop gene therapy to treat cystic fibrosis.